Silybum marianum provides cardioprotection and limits adverse remodeling post-myocardial infarction by mitigating oxidative stress and reactive fibrosis
Por:
Vilahur, G, Casani, L, Pena, E, Crespo, J, Juan-Babot, O, Ben-Aicha, S, Mendieta, G, Bejar, MT, Borrell, M, Badimon, L
Publicada:
1 nov 2018
Resumen:
Aims: Milk thistle (Silybum marianum; SM) is an herb commonly used for hepatoprotection with antioxidant and antifibrotic properties. We investigated in pigs the cardiac effects of SM intake during the acute phase of myocardial infarction (MI) and remodeling period post-MI.
Methods: Study-1 tested the effect of SM use on the acute phase of MI. Hence, animals were distributed to a control group or to receive SM prior infarction (1.5 h ischemia). Animals were sacrificed after 2.5 h of reperfusion. Study-2 tested the effect of SM use in the cardiac remodeling phase. Accordingly, animals received for 10 d diet +/- SM prior MI and followed the same regime for 3weeks and then sacrificed. Study-3 tested the effect of SM in a non-infarcted heart; therefore, animals received for 10 d diet +/- SM and then sacrificed.
Results: Animals taking SM before MI showed a reduction in cardiac damage (decreased oxidative damage, ROS production and xanthine oxidase levels; preserved mitochondrial function; and increased myocardial salvage; p < 0.05) versus controls. Animals that remained on chronic SM intake post-MI improved left ventricular remodeling. This was associated with the attenuation of the TGF beta(1)/T beta Rs/SMAD2/3 signaling, lower myofibroblast transdifferentiation and collagen content in the border zone (p < 0.05 vs. all other groups). Cardiac contractility improved in animals taking SM (p < 0.05 vs. post-MI-control). No changes in cardiac function or fibrosis were detected in animals on SM but without MI.
Conclusion: Intake of SM protects the heart against the deleterious effects of an MI and favors cardiac healing. These benefits may be attributed to the antioxidant and antifibrotic properties of SM. (c) 2018 Elsevier B.V. All rights reserved.
Filiaciones:
Vilahur, G:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Inst Salud Carlos III, CIBERCV, Madrid, Spain
Casani, L:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Inst Salud Carlos III, CIBERCV, Madrid, Spain
Pena, E:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Inst Salud Carlos III, CIBERCV, Madrid, Spain
Crespo, J:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Juan-Babot, O:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Ben-Aicha, S:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Mendieta, G:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Bejar, MT:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Borrell, M:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Inst Salud Carlos III, CIBERCV, Madrid, Spain
Badimon, L:
IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC, IIB St Pau, Barcelona, Spain
Inst Salud Carlos III, CIBERCV, Madrid, Spain
Autonomous Univ Barcelona, Cardiovasc Res Chair UAB, Barcelona, Spain
|